Clinical trial
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic…
NCT00199043 · Goethe University, Other · Completed
Key facts
| NCT number | NCT00199043 |
|---|---|
| Title | Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma |
| Official title | Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs) |
| Lead sponsor | Goethe University, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adult Acute Lymphocytic Leukemia, High-grade Lymphoma |
| Intervention type | Drug |
| Interventions | Allopurinol, Rasburicase |
| Enrollment | 80 |
| Start date | May 1, 2003 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 17, 2023 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: